Compare AGO & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGO | TFX |
|---|---|---|
| Founded | 2003 | 1943 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.6B |
| IPO Year | 2003 | 1994 |
| Metric | AGO | TFX |
|---|---|---|
| Price | $86.73 | $119.32 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 10 |
| Target Price | $101.00 | ★ $137.11 |
| AVG Volume (30 Days) | 217.3K | ★ 931.1K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 1.58% | 1.22% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.73 | N/A |
| Revenue | $872,000,000.00 | ★ $3,047,324,000.00 |
| Revenue This Year | $4.22 | $9.54 |
| Revenue Next Year | N/A | $10.52 |
| P/E Ratio | $11.16 | ★ N/A |
| Revenue Growth | N/A | ★ 2.45 |
| 52 Week Low | $74.09 | $100.18 |
| 52 Week High | $92.40 | $143.32 |
| Indicator | AGO | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 50.76 | 65.36 |
| Support Level | $82.78 | $117.58 |
| Resistance Level | $89.44 | $126.71 |
| Average True Range (ATR) | 1.70 | 4.69 |
| MACD | 0.04 | 1.50 |
| Stochastic Oscillator | 40.20 | 95.68 |
Assured Guaranty Ltd. provides credit protection products to the United States and international public finance and structured finance markets and manages assets across collateralized loan obligations as well as opportunity funds and liquid funds that build on its corporate credit, asset-based finance, municipal, and healthcare experience. The company operates in two segments: the Insurance segment and the Asset Management segment. The majority of the revenue earned by the company is from the Insurance segment.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.